Can Melatonin Be a Potential "Silver Bullet" in Treating COVID-19 Patients?

被引:52
作者
Cardinali, Daniel P. [1 ]
Brown, Gregory M. [2 ]
Pandi-Perumal, Seithikurippu R. [3 ]
机构
[1] Pontificia Univ Catolica Argentina, Fac Med Sci, RA-1007 Buenos Aires, DF, Argentina
[2] Univ Toronto, Dept Psychiat, Ctr Addict & Mental Hlth, Toronto, ON M5T 1R8, Canada
[3] Somnogen Canada Inc, Coll St, Toronto, ON M6H 1C5, Canada
关键词
aging; anti-SARS-CoV-2; vaccination; chronotherapy; COVID-19; pandemic; cytoprotection; diabetes; inflammation; metabolic syndrome; melatonin; cognitive impairment; neurodegeneration; oxidative stress; renin-angiotensin system; RENIN-ANGIOTENSIN SYSTEM; SLEEP DISTURBANCES; OXIDATIVE STRESS; INHIBITION; EXPRESSION; MOLECULE; DELIRIUM; DISEASE; CANCER; CELLS;
D O I
10.3390/diseases8040044
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The therapeutic potential of melatonin as a chronobiotic cytoprotective agent to counteract the consequences of COVID-19 infections has been advocated. Because of its wide-ranging effects as an antioxidant, anti-inflammatory, and immunomodulatory compound, melatonin could be unique in impairing the consequences of SARS-CoV-2 infection. Moreover, indirect evidence points out to a possible antiviral action of melatonin by interfering with SARS-CoV-2/angiotensin-converting enzyme 2 association. Melatonin is also an effective chronobiotic agent to reverse the circadian disruption of social isolation and to control delirium in severely affected patients. As a cytoprotector, melatonin serves to combat several comorbidities such as diabetes, metabolic syndrome, and ischemic and non-ischemic cardiovascular diseases, which aggravate COVID-19 disease. In view of evidence on the occurrence of neurological sequels in COVID-19-infected patients, another putative application of melatonin emerges based on its neuroprotective properties. Since melatonin is an effective means to control cognitive decay in minimal cognitive impairment, its therapeutic significance for the neurological sequels of SARS-CoV-2 infection should be considered. Finally, yet importantly, exogenous melatonin can be an adjuvant capable of augmenting the efficacy of anti-SARS-CoV-2 vaccines. We discuss in this review the experimental evidence suggesting that melatonin is a potential "silver bullet" in the COVID 19 pandemic.
引用
收藏
页数:15
相关论文
共 119 条
  • [1] Abbas A., 2019, BASIC IMMUNOLOGY
  • [2] Extrapineal melatonin: sources, regulation, and potential functions
    Acuna-Castroviejo, Dario
    Escames, Germaine
    Venegas, Carmen
    Diaz-Casado, Maria E.
    Lima-Cabello, Elena
    Lopez, Luis C.
    Rosales-Corral, Sergio
    Tan, Dun-Xian
    Reiter, Russel J.
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2014, 71 (16) : 2997 - 3025
  • [3] Melatonin as a potential modulator of Nrf2
    Ahmadi, Zahra
    Ashrafizadeh, Milad
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (01) : 11 - 19
  • [4] Chronotherapy of Non-Steroidal Anti-Inflammatory Drugs May Enhance Postoperative Recovery
    Al-Waeli, H.
    Nicolau, B.
    Stone, L.
    Abu Nada, L.
    Gao, Q.
    Abdallah, M. N.
    Abdulkader, E.
    Suzuki, M.
    Mansour, A.
    Al Subaie, A.
    Tamimi, F.
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [5] Structural and physico-chemical evaluation of melatonin and its solution-state excited properties, with emphasis on its binding with novel coronavirus proteins
    Al-Zaqri, Nabil
    Pooventhiran, T.
    Alsalme, Ali
    Warad, Ismail
    John, Athira M.
    Thomas, Renjith
    [J]. JOURNAL OF MOLECULAR LIQUIDS, 2020, 318
  • [6] Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome
    Alexopoulos, Harry
    Magira, Eleni
    Bitzogli, Kleopatra
    Kafasi, Nikolitsa
    Vlachoyiannopoulos, Panayiotis
    Tzioufas, Athanasios
    Kotanidou, Anastasia
    Dalakas, Marinos C.
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (06):
  • [7] Ebola Virus: Melatonin as a Readily Available Treatment Option
    Anderson, George
    Maes, Michael
    Markus, Regina P.
    Rodriguez, Moses
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2015, 87 (04) : 537 - 543
  • [8] CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2
    Antony, PA
    Restifo, NP
    [J]. JOURNAL OF IMMUNOTHERAPY, 2005, 28 (02) : 120 - 128
  • [9] Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
    Arendse, Lauren B.
    Danser, A. H. Jan
    Poglitsch, Marko
    Touyz, Rhian M.
    Burnett, John C., Jr.
    Llorens-Cortes, Catherine
    Ehlers, Mario R.
    Sturrock, Edward D.
    [J]. PHARMACOLOGICAL REVIEWS, 2019, 71 (04) : 539 - 570
  • [10] The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies
    Bald, Tobias
    Krummel, Matthew F.
    Smyth, Mark J.
    Barry, Kevin C.
    [J]. NATURE IMMUNOLOGY, 2020, 21 (08) : 835 - 847